Stock Ratings / Health Care / AORT / options

PRCT (48) IRMD (68) SGP (41) DRTS (33) ⌘ Pro Terminal →

Artivion Inc. (AORT) Options Positioning, Max Pain & Unusual Sweeps

$23.44 +2.27% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $23.49

Artivion Inc. (AORT) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.14B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $23.49 (+0.22%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AORT)Realized 20D OHLCV Swing Band: ±9.4%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY AORT SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (28% of score)

FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 46.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (24% of score)

20D Institutional Volume Accumulation (±9.4% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 7.6% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$21.26+2.4% Next Q

Q2 (-2Q)

Grade D$21.78+7% Next Q

Q3 (-1Q)

Grade C-$23.30+0.6% Next Q

Current

Grade D+$23.44-0.7% Hist 90D α

Trajectory: D (46) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AORT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AORT currently carries a cautious 54/100 (D+) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.87) and Max Pain ($24.61) forces dealer call-delta covering toward $50.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AORT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AORT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.4%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AORT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AORT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AORT)

✓Walkthrough of AORT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AORT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.58%⚡ TESTING RESISTANCE

2026-10-30O $23.62H $23.62L $21.85C $23.44VOL 627.4K

RES: $23.45SUP: $20.36SMA50: $23.87SMA200: $29.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AORT Butterfly Map → + Track AORT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AORT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AORT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AORT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AORT)

Health Care Rank #293 of 1016 ⚔️ PRCT vs AORT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AORT vs. PRCT, IRMD, SGP, DRTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Artivion Inc. (AORT) ranks #293 by composite RQD confidence (54/100, grade D+) and #344 by equity capitalization ($1.14B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with AORT at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AORT ACTIVE Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	Benchmark Subject
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-aort →
IRMD iRadimed Corporation	C+	68/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	/irmd-vs-aort →
SGP SpyGlass Pharma Inc.	D-	41/100	—	—	-35.0%	-1.06%	$1.09B	/sgp-vs-aort →
DRTS Alpha Tau Medical Ltd.	E	33/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-aort →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000784199

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artivion Inc. (AORT) reported GAAP revenue of $441.3M (+13.6% vs. FY2024 revenue of $388.5M , and +24.7% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $39.9M, and free cash flow of $839.0K (-92.4% YoY). On the balance sheet, AORT closed FY2025 with $884.8M in total assets against $215.1M in total debt (Altman Z-Score: 2.46, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$441.3M	$9.8M	$39.9M	$839.0K	$884.8M	$215.1M
FY2024 (FY)	2024-12-31	$388.5M	-$13.4M	$22.2M	$11.0M	$789.1M	$314.2M
FY2023 (FY)	2023-12-31	$354.0M	-$30.7M	$18.8M	$18.8M	—	—

3. AORT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Artivion Inc. (NYSE: AORT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $23.44 (+2.27% 1D, market cap $1.14B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, AORT ranks #293 in composite RQD confidence.

How does AORT compare to PRCT and IRMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), AORT carries a Roarable D+ (54/100 RQD), trailing P/E of 117.0x, gross margin of 64.4%, and ROIC of 4.5%. By comparison, PRCT (PROCEPT BioRobotics Corporation) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B) and IRMD (iRadimed Corporation) posts a C+ grade (68/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AORT?

Per AORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000784199), Artivion Inc. generated $441.3M in revenue (+13.6% YoY), $9.8M in net income, and $839.0K in free cash flow against $884.8M in total assets and $215.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AORT trading relative to its 50-day, 200-day, and 52-week technical levels?

AORT last traded at $23.44 (+2.27% on volume of 418,218 shares), positioning the stock -1.80% below its 50-day simple moving average ($23.87) and -20.24% below its 200-day simple moving average ($29.39). Across its 52-week range of $19.16 to $48.25, AORT sits at the 14.7% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($21.24 to $25.64).

AORT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AORT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AORT.

Direct Sub-Reports: AORT RQD Cockpit AORT 12M Forecast AORT Earnings & Move AORT Dividends & DRIP AORT Insiders & 13F AORT Whale Options AORT Profit Sankey AORT News & Why